PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests a new drug, BPI-572270, in 120 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The goal is to see if the drug is safe and can shrink tumors. Participants must have already tried standard treatments…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New drug targets tough pancreatic cancer in phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called HLX43 in 100 adults with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload to kill them. The main goals are to find the best dose and se…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Targeted chemo delivery could boost pancreatic cancer surgery success
Disease control Not yet recruitingThis early-stage trial tests whether delivering a standard chemotherapy drug (gemcitabine) directly to the tumor through a special catheter can improve outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, fo…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: University of Vermont • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New hope for stomach, colon, and pancreatic cancers? trial launches
Disease control Not yet recruitingThis study tests a new drug called SSGJ-706 combined with standard treatments for people with advanced stomach, colon, pancreatic, or esophageal cancers that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth.…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
Does draining the bile duct before surgery help pancreatic cancer patients?
Knowledge-focused Not yet recruitingThis study looks at whether draining a blocked bile duct before surgery affects tumor features and survival in people with pancreatic cancer. Researchers will review medical records of 90 patients who had their pancreatic tumor removed. The goal is to understand if pre-operative …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated May 01, 2026 16:00 UTC
-
Simple hand grip test may reveal hidden clues in pancreatic cancer
Knowledge-focused Not yet recruitingThis study looks at whether measuring hand grip strength in adults with pancreatic cancer can give doctors useful information about how the disease and treatment are progressing. About 50 participants will squeeze a handheld device during regular clinic visits and answer question…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC